Orthofix Medical Inc. completed the transactions contemplated by the definitive Agreement and Plan of Merger, dated as of October 10, 2022 (the “ Merger Agreement”), by and among Orthofix, Orca Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Orthofix (“ Merger Sub”) and SeaSpine Holdings Corporation, a Delaware corporation (“ SeaSpine”). Pursuant to the Merger Agreement, Orthofix and SeaSpine combined through a merger of SeaSpine with and into Merger Sub, with Merger Sub continuing as the surviving entity and a wholly owned subsidiary of Orthofix (the “ Merger”). On January 3, 2023, the board of directors of Orthofix (the “ Board”) appointed Keith C. Valentine as Orthofix's President (succeeding Jon C. Serbousek, who will now serve as Executive Chairman), and Patrick L. Keran as Orthofix's Chief Legal Officer (succeeding Kimberley A. Elting, who will now serve as President, Global Orthopedics).

Each of the foregoing appointments were contingent upon, and became effective as of, the closing of the Merger at the Effective Time. Keith C. Valentine, 55, served as SeaSpine's Chief Executive Officer from May 2015 to January 2023 and President from July 2015 to January 2023. He also served on SeaSpine's board of directors from May 2015 to January 2023.

While at SeaSpine, Mr. Valentine oversaw SeaSpine's formational spin-off transaction and oversaw the development and launch of numerous new products. Prior to joining SeaSpine, Mr. Valentine served as President and Chief Operating Officer of NuVasive Inc. from January 2007 to January 2015 and as President from December 2004 to January 2007, prior to which he served in various senior executive roles in marketing, development and operations since joining NuVasive in 2001. Previously, Mr. Valentine served as Vice President of Marketing at ORATEC Interventions Inc., a medical device company acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic Sofamor Danek including, Vice President of Marketing for the Rods Division and Group Director for the BMP Biologics program, the Interbody Sales Development Effort, and International Sales and Marketing.

Mr. Valentine currently serves on the board of directors of SI-BONE Inc., a publicly traded medical device company focused on the treatment of musculoskeletal disorders of the sacro-pelvic anatomy, and serves as chair of its nominating and governance committee. Mr. Valentine received a B.B.A. in Management and Biomedical Sciences from Western Michigan University. Patrick L. Keran, 51, served as SeaSpine's General Counsel from October 2015 to January 2023, Secretary from June 2016 to January 2023, and Senior Vice President from June 2020 to January 2023.

While at SeaSpine, Mr. Keran, oversaw all legal, corporate governance, and compliance matters. Prior to joining SeaSpine, Mr. Keran provided strategic and business advisory services to a variety of life sciences companies, including acting as Chief Legal Officer to NAIA Pharmaceuticals Inc., a privately held international drug development company. From February 2010 to February 2015, Mr. Keran served as President and Chief Operating Officer of Mast Therapeutics Inc., a publicly held clinical stage biopharmaceutical company, and from August 2006 to February 2010, he served as its General Counsel.

He also served as Mast's Secretary from September 2006 to February 2015 and as its principal financial officer from July 2009 to January 2013. Previously, from 2004 to 2006, Mr. Keran was Associate General Counsel at Ionis Pharmaceuticals Inc. (formerly known as Isis Pharmaceuticals Inc.), a publicly held drug discovery and development company. From 1999 to 2004, Mr. Keran practiced corporate law at the law firms of Heller Ehrman LLP and Brobeck Phleger & Harrison LLP, specializing in public and private financings, licensing arrangements, mergers and acquisitions and corporate governance matters.

Mr. Keran is licensed to practice law in the State of California. Mr. Keran received a B.A. from the University of California at San Diego and a J.D. from the University of California at Berkeley, Boalt Hall School of Law. In connection with the Merger and effective as of the Effective Time, Wayne Burris, Lilly Marks, John E. Sicard and Thomas A. West resigned as directors of Orthofix.

The decision to resign by each of Ms. Marks and Messrs. Burris, Sicard, and West is not because of a disagreement with Orthofix or the Board on any matter relating to Orthofix's operations, policies or practices. On January 3, 2023, consistent with the terms of the Merger Agreement, the Board approved the appointments of Mr. Valentine, Stuart M. Essig, Ph.D., John B. Henneman, III and Shweta Singh Maniar to fill the vacancies created by resignations of Mr. Burris, Ms. Marks, Mr. Sicard, and Mr. West, in each case subject to consummation of the Merger and effective immediately following the Effective Time.

These appointments, which were consistent with recommendations made by the Board's Nominating, Governance and Sustainability Committee, became effective on January 5, 2023. Catherine M. Burzik, Jason M. Hannon, James F. Hinrichs, Michael E. Paolucci and Mr. Serbousek remain as continuing directors. Each new and continuing director will serve until the 2023 annual meeting of Orthofix's stockholders and until his or her successor is duly elected and qualified.

Ms. Burzik, who previously served as Chair of the Board, was appointed Lead Independent Director, and Mr. Serbousek was appointed as Executive Chairman of the Board.